Canadian Cosmetic Products Regulations
Health Canada Cosmetics
Cosmetic Products made available in the Canadian market are regulated by Health Canada and need to comply with the Food and Drugs Act, the Cosmetic Regulation and the Consumer Packaging and Labelling Act. All cosmetic products must not pose a risk to consumers. Therefore, they need to be manufactured, prepared, preserved, packed and stored under rigorous sanitary conditions.
Picture of Marta Pinto

Marta Pinto

Regulatory Affairs Associate


Health Canada is the entity that regulates cosmetics in Canada, monitoring production and distribution in several sectors. Cosmetics made available in Canada must meet the requirements set out in the Food and Drugs Act and the Cosmetic Regulations. Moreover, cosmetic products must follow the requirements outlined in the Consumer Packaging and Labelling Act and its associated Regulations. The chemicals present in cosmetic and personal care products may be subject to the Canadian Environmental Protection Act.

Every cosmetic must be safe to use and must not pose any health risk, so both regulations require that cosmetics sold in Canada are manufactured, prepared, preserved, packed and stored under sanitary conditions. The responsibility to prove and demonstrate the safety of the product is of the manufacturer/importer. They need to be aware of emerging science and risks related to substances in the cosmetics they sell.

According to the Food and Drugs Act, a cosmetic is defined as “any substance or mixture of substances, manufactured, sold or represented for use in cleansing, improving or altering the complexion, skin, hair or teeth and includes deodorants and perfumes”. Cosmetics used by professional esthetic services, bulk institutional products such as hand soap in school rest rooms and “handmade” cosmetics sold through home-base businesses or craft sales, are also included in this definition and are, consequently, considered cosmetic products. Sunscreens, acne treatments, antidandruff shampoos, skin whiteners or lighteners and hand sanitizers are examples of products that are not considered cosmetics in Canada.

No pre-market cosmetic registration needs to be made in Canada, but a notification must be made by the manufacturer/importer to Health Canada informing that they are selling a product (domestically manufactured or abroad). The notification is made using the Cosmetic Notification Form (CNF), within 10 days of being placed in the market. Non-compliance with this requirement can lead to a denied entry into the country or a withdrawal of the cosmetic from the Canadian market. The identity of the product, function, list of ingredients and concentration, form of the cosmetic, product category, name and address of the manufacturer and distributor, are some of the information that needs to be presented in the notification process.

A list of the product’s ingredients needs to be provided to Health Canada (by the manufacturer or importer) and included in the label, allowing consumers to identify and avoid cosmetics with ingredients that are of concern to them. Health Canada regulates cosmetic ingredients, prohibiting and limiting the use of ingredients that present health risks.

The Cosmetic Ingredient Hotlist is an administrative tool that Health Canada uses to communicate to manufacturers and others that certain substances may be prohibited or restricted in cosmetics (up to a certain concentration or under certain conditions, along with warnings they need to display). Entries on the Hotlist can be linked to particular legislative provisions (e.g., Section 16 of the Food and Drug Act).

The label of cosmetic products needs to comply with all the specific requirements set out by the Food and Drugs Act, the Cosmetic Regulations, the Consumer Packaging and Labelling Act and the Consumer Packaging and Labelling Regulations. Between other information, the label must indicate:

  • The list of ingredients (using the INCI system)
  • The identity of the product (in English and French)
  • A statement of net quantity (in metric units of measurement)
  • The name and address of the manufacturer or distributor
  • Warnings or cautions (in English and French)
  • Directions for safe use of the product (in English and maybe in French, depending on the province)

Canada has two official languages, so companies should pay special attention to the language on the label, as some parts also need to be written in French (could vary from province to province).

Post-market surveillance processes are put in place by Health Canada in order to identify potential safety issues related to cosmetic products. When consumer and trade complaints are made to Health Canada, inspectors receive and investigate the cases to ensure that those cosmetics are compliant with the law. The Consumer Product Safety Program from Health Canada identifies, assesses, manages and communicates risks to human health or safety of consumer products and cosmetics after they reach the consumer market. The Program carries out its risk-assessment function, gathering information from a variety of sources.


Earlier this year, it was announced the Toxic Substances Warning Label Act (Bill C-266). This Bill is described as “an Act regarding the right to know when products contains toxic substances” and sets out a prohibition on the sale, importation, and advertisement of any product containing a toxic substances or that produces a toxic substance during its use. This does not apply when the product has a label warning of the potential exposure to the toxic substance affixed on one or more surfaces of its packaging.

A public consultation went through in Canada, in order to obtain comments on the 2021 to 2028 agenda to reduce volatile organic compounds (VOC) in consumer and commercial products. Currently Canada does not have regulations in place to limit VOC emissions from certain product categories and meet its commitments under the Ozone Annex to the Canada-United States Air Quality Agreement. According to the Government of Canada, “The existing voluntary guidelines recommending VOC concentration limits for consumer product categories have not been sufficient in meeting these objectives”.

Critical Catalyst has a team of regulatory experts that can help you with this and other markets. Do not hesitate to contact us at


  1. Food and Drugs Act. R.S.C., 1985, c. F-27. 2021. Available from:
  2. Cosmetic Regulations. C.R.C., c. 869. 2019. Available from:,_c._869/page-1.html
  3. Regulatory information for cosmetics. Government of Canada. Available from:


medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »